Literature DB >> 29706566

FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice.

Xuebo Pan1, Yihui Shao2, Fan Wu3, Yuan Wang2, Rongrong Xiong4, Jujia Zheng4, Haishan Tian4, Baile Wang5, Yanfang Wang3, Yi Zhang4, Zongsheng Han6, Aijuan Qu7, Haixia Xu8, Aihua Lu9, Tianxin Yang10, Xiaokun Li11, Aimin Xu5, Jie Du2, Zhuofeng Lin12.   

Abstract

Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on glucose and lipid metabolism and insulin sensitivity. However, the role of FGF21 in hypertension remains elusive. Here we show that FGF21 deficiency significantly exacerbates angiotensin II-induced hypertension and vascular dysfunction, whereas such negative effects are reversed by replenishment of FGF21. Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage. In addition, ACE2 deficiency strikingly abrogates these beneficial effects of FGF21 in mice, including alleviation of angiotensin II-associated hypertension and vascular damage. Otherwise, pharmaceutical inhibition of angiotensin-(1-7) attenuates the protective effect of FGF21 on angiotensin II-induced vascular dysfunction, but not on hypertension. Thus, FGF21 protects against angiotensin II-induced hypertension and vascular impairment by activation of the ACE2/angiotensin-(1-7) axis via fine-tuning the multi-organ crosstalk between liver, adipose tissue, kidney, and blood vessels.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACE2; FGF21; angiotensin II; angiotensin-(1–7); hypertension

Mesh:

Substances:

Year:  2018        PMID: 29706566     DOI: 10.1016/j.cmet.2018.04.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  39 in total

Review 1.  Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota.

Authors:  Rachel M Golonka; Xia Xiao; Ahmed A Abokor; Bina Joe; Matam Vijay-Kumar
Journal:  J Nutr Biochem       Date:  2020-02-22       Impact factor: 6.048

Review 2.  Mouse Models of Heart Failure with Preserved or Reduced Ejection Fraction.

Authors:  Natalie A Noll; Hind Lal; W David Merryman
Journal:  Am J Pathol       Date:  2020-04-25       Impact factor: 4.307

Review 3.  Growth Factors as Immunotherapeutic Targets in Cardiovascular Disease.

Authors:  John E Mindur; Filip K Swirski
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-16       Impact factor: 8.311

Review 4.  The roles of FGF21 in atherosclerosis pathogenesis.

Authors:  Farzane Shanebandpour Tabari; Ansar Karimian; Hadi Parsian; Vahid Rameshknia; Ata Mahmoodpour; Maryam Majidinia; Mahmood Maniati; Bahman Yousefi
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

5.  FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

Authors:  Fanrui Meng; Mir Hassan Khoso; Kai Kang; Qi He; Yukai Cao; Xinghao Jiang; Wei Xiao; Deshan Li
Journal:  Mol Biol Rep       Date:  2021-09-18       Impact factor: 2.316

Review 6.  Fibroblast growth factor 21 in heart failure.

Authors:  William Tucker; Bradley Tucker; Kerry-Anne Rye; Kwok Leung Ong
Journal:  Heart Fail Rev       Date:  2022-08-27       Impact factor: 4.654

7.  Refined-JinQi-JiangTang tablet ameliorates hypertension through activation of FGF21/FGFR1 axis in fructose-fed rats.

Authors:  Siming Li; Xiaoling Li; Jing Fan; Xinhang Jia; Hemeng Wang; Fangxin Dong; Haoyang Mao; Chen Zhang; Wenfei Wang; Ye Jiang; Lijun Yan; Na Zhang
Journal:  J Nat Med       Date:  2022-05-09       Impact factor: 3.192

8.  The E3 ubiquitin ligase TRIM31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of MAP3K7 in the TGF-β1 signaling pathway.

Authors:  Jie Zhang; Lei Cao; Xiaohong Wang; Qian Li; Meng Zhang; Cheng Cheng; Liwen Yu; Fei Xue; Wenhai Sui; Shangwen Sun; Na Li; Peili Bu; Bingyu Liu; Fei Gao; Junhui Zhen; Guohai Su; Cheng Zhang; Chengjiang Gao; Meng Zhang; Yun Zhang
Journal:  Cell Death Differ       Date:  2021-09-28       Impact factor: 12.067

9.  Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery.

Authors:  Wei Xie; Dan Li; Yaru Shi; Ning Yu; Yu Yan; Yingchao Zhang; Qiongli Yu; Yulin Li; Jie Du; Zhuofeng Lin; Fan Wu
Journal:  Front Cardiovasc Med       Date:  2022-04-06

10.  FGF21 alleviates pulmonary hypertension by inhibiting mTORC1/EIF4EBP1 pathway via H19.

Authors:  Xiuchun Li; Yaxin Zhang; Lihuang Su; Luqiong Cai; Chi Zhang; Jianhao Zhang; Junwei Sun; Mengyu Chai; Mengsi Cai; Qian Wu; Chi Zhang; Xiaoqing Yan; Liangxing Wang; Xiaoying Huang
Journal:  J Cell Mol Med       Date:  2022-04-19       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.